<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01836861</url>
  </required_header>
  <id_info>
    <org_study_id>IPI-145-05</org_study_id>
    <secondary_id>2012-005425-75</secondary_id>
    <nct_id>NCT01836861</nct_id>
  </id_info>
  <brief_title>IPI-145 ADME and Absolute Bioavailability Study</brief_title>
  <official_title>A Phase 1, Open-Label Study of the Absorption, Distribution, Metabolism and Excretion of 14C-Labeled IPI-145 and the Absolute Bioavailability of IPI-145 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Verastem, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Verastem, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, 2-period, absorption, distribution, metabolism and excretion (ADME)
      and absolute bioavailability study in 6 healthy adult male subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In Period 1, subjects will receive a single oral dose of 25 mg IPI-145, followed by a
      15-minute IV infusion of approximately 2.8 μg 14C-IPI-145 containing 14.8 kBq of
      radioactivity.

      In Period 2, the same subjects will receive a single dose of 25 mg 14C-IPI-145 as an oral
      suspension, containing approximately 3.15 MBq of radioactivity.

      There will be a washout period of at least 14 days between Period 1 and Period 2.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK parameters (AUC) of IPI-145 in plasma</measure>
    <time_frame>over 48 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters (AUC) and radioactivity excreted in urine and feces</measure>
    <time_frame>over 144 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters (Cmax) of IPI-145 in plasma</measure>
    <time_frame>over 48 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters (t1/2) of IPI-145 in plasma</measure>
    <time_frame>over 48 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters (Cmax) and radioactivity excreted in urine and feces</measure>
    <time_frame>over 144 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters (t1/2) and radioactivity excreted in urine and feces</measure>
    <time_frame>over 144 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events following a single dose administration of IPI-145</measure>
    <time_frame>over 4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>IPI-145 and [14C] IPI-145</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IPI-145</intervention_name>
    <description>Intravenous infusion: approximately 2.8 μg IPI-145 containing 14.8 kBq of radioactivity; Oral suspension: 25 mg IPI-145 containing approximately 3.15 MBq of radioactivity; Oral capsule: 25 mg IPI-145</description>
    <arm_group_label>IPI-145 and [14C] IPI-145</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males, between 18 and 45 years of age, inclusive Body Mass Index (BMI) : 18.0-30.0
             kg/m2

          -  In good health, determined by no clinically significant findings from medical history,
             physical examination (Check-in), 12-lead ECG, and vital signs

          -  Provision of signed and dated, written informed consent prior to any study specific
             procedures

        Exclusion Criteria:

          -  Evidence of clinically significant medical conditions

          -  History of gastrointestinal surgery that may affect drug absorption

          -  Positive or indeterminate QuantiFERON-TB Gold test at screening

          -  Any active infection at the time of screening or admission

          -  Participation in another ADME study with a radiation burden &gt;0.1 mSv in the period of
             1 year before screening

          -  Irregular defecation pattern (less than once per 2 days)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan-Jaap van Lier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pharmaceuticals Research Association (PRA), BV</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hagop Youssoufian, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Verastem, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pharmaceuticals Research Association (PRA)</name>
      <address>
        <city>Zuidlaren</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2013</study_first_submitted>
  <study_first_submitted_qc>April 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2013</study_first_posted>
  <last_update_submitted>July 28, 2017</last_update_submitted>
  <last_update_submitted_qc>July 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase I</keyword>
  <keyword>healthy male volunteers</keyword>
  <keyword>ADME</keyword>
  <keyword>Bioavailability</keyword>
  <keyword>PI3K inhibitor</keyword>
  <keyword>Absorption</keyword>
  <keyword>Distribution</keyword>
  <keyword>Metabolism</keyword>
  <keyword>Excretion</keyword>
  <keyword>safety</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

